Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation


YEGİN Z. A. , ÖZKURT Z. N. , Aki S. Z. , Sucak G. T.

TRANSFUSION AND APHERESIS SCIENCE, cilt.42, sa.3, ss.239-245, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 42 Konu: 3
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1016/j.transci.2010.03.011
  • Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
  • Sayfa Sayıları: ss.239-245

Özet

Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell transplantation (HSCT). In this retrospective study, 23 patients 115 (65.2%) AML, 8 (34.8%) ALL] who received DLI +/- reinduction chemotherapy for post-transplant relapse were reviewed. The overall response rate of DLI was 66.7% for AML and 50% for ALL A total of 15 patients (65.2%) developed acute graft versus host disease (GVHD). Response rates were higher in patients with GVHD (80% versus 25%; p = 0.01; OR: 12.0). The probability of OS was better in patients who respond to DLI (p = 0.04). Further strategies are required to improve the anti-tumor properties of alloreactive donor lymphocytes and to obtain durable responses with DLI in patients with relapsed acute leukemia after allogeneic HSCT. (C) 2010 Elsevier Ltd. All rights reserved.